Articles

Karyopharm Articles

January 13, 2020BenzingaNews

Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update

-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and betw... See more »
December 27, 2019The Pharma LetterNews

Karyopharm submits NDA for Xpovio as DLBCL treatment

Cancer-focused Karyopharm Therapeutics has submitted a New Drug Application (NDA) to the US Food and.... See more »
December 23, 2019BioPortfolioNews

FDA Approval Sought for Selinexor in DLBCL

An application has been submitted to the FDA for selinexor for the treatment of patients with relapse... See more »
December 8, 2019MarketScreenerNews

Karyopharm Presents XPOVIO� (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting

(marketscreener.com) -- Once-Weekly Oral Selinexor in Combination with Weekly Kyprolis® and Low Dose ... See more »
November 4, 2019ReutersNews

Karyopharm exceeds analyst expectations for first cancer drug launch

Cancer drug maker Karyopharm Therapeutics Inc on Monday reported revenues of $12.8 million for its th... See more »
November 1, 2019MarketScreenerNews

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

(marketscreener.com) NEWTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (N... See more »
October 28, 2019BenzingaNews

Karyopharm to Report Third Quarter 2019 Financial Results on November 4, 2019

NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), an oncol... See more »
October 8, 2019PR NewswirePress Release

XPOVIO (selinexor) Now Available to Excelera Network Members for Treatment of Relapsed or Refectory Multiple Myeloma

MINNEAPOLIS, Oct. 8, 2019 /PRNewswire/ -- The Excelera Network was selected by Karyopharm Therapeutic... See more »
October 1, 2019BioPortfolioNews

AmerisourceBergen Selected by Karyopharm to Support XPOVIO

New rare disease therapy supported by AmerisourceBergens unified offerings including specialty pharma... See more »
September 23, 2019BenzingaNews

The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Karyopharm Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, Sept. 23, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights li... See more »
September 3, 2019StreetInsiderPress Release

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clin... See more »
August 29, 2019GlobalNewswirePress Release

ROSEN, A TOP RANKED LAW FIRM, Reminds Karyopharm Therapeutics Inc. Investors of Important September 23rd Deadline in Securities Class Action - KPTI

NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, remind... See more »
August 21, 2019GlobalNewswirePress Release

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

NEW YORK, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law f... See more »
August 15, 2019CentralChartsPress Release

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Karyopharm Therape... See more »
July 26, 2019CentralChartsPress Release

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therape... See more »
April 1, 2019StreetInsiderPress Release

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced... See more »
February 28, 2019GlobeNewswirePress Release

Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

-- FDA Advisory Committee Votes 8 to 5 Recommending FDA Wait for the Results from the OngoingPhase 3 ... See more »
February 4, 2019streetinsiderPress Release

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEWTON, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clini... See more »
January 2, 2019StreetInsiderPress Release

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Each of the stock options has an exercise price of $9.37 per share, the closing price of Karyopharm’s... See more »
Loading interface...
Loading interface...
Loading interface...
Loading interface...